Development of stability-indicating UHPLC method for the quantitative determination of silodosin and its related substances

Journal of Chromatographic Science

Volumn 52, Issue 7, 2014, Pages 646-653

  Shaik, Jafer Vali ^a,b   Saladi, Shantikumar ^d   Sait, Shakil S ^c  

^a Sri Biotech Laboratories India Limited   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

^c DR REDDY'S LABORATORIES LTD   (India)

^d NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLE DERIVATIVE; SILODOSIN;

CHEMISTRY; DRUG CONTAMINATION; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; DRUG STABILITY; INDOLES; LIMIT OF DETECTION; LINEAR MODELS; REPRODUCIBILITY OF RESULTS;

EID: 84904332807     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/bmt094     Document Type: Article

References (13)

1. Yoshida, M., Homma, Y., Kawabe, K.; Silodosin, a novel selective alpha 1A-Adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia; Expert Opinion on Investigational Drugs, (2007); 16: 1955-1965. (Pubitemid 351403726)
2. Kazuki, K., Masaki, Y., Yukio, H.; Silodosin, a new a1A- Adrenoceptorselective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men; British Journal of Urology International, (2006); 98: 1019-1024.
3. Masaki, Y., Imao, M., Katsuyoshi, A., Junzo, K.; Silodosin a selective a1A adrenoceptor antagonist for treatment of benign prostatic hyperplasia. In Xianhai, H., Robert, G. (eds). Case studies in modern drug discovery and development. John Wiley & Sons, Somerset, NJ, (2012); 360-390.
4. Roehrborn, C.G., Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH); Medical Clinics of North America, (2011); 95: 87-100.
5. Sausville, J., Naslund, M.; Benign prostatic hyperplasia and prostate cancer: an overview for primary care physicians; International Journal of Clinical Practice, (2010); 64: 1740-1745.
6. McVary, K.T., Roehrborn, C.G., Avins, A.L.; Update on AUA guideline on the management of benign prostatic hyperplasia; Journal of Urology, (2011); 185: 1793-803.
7. National Institute of Diabetes and Digestive and Kidney Diseases; Prostate enlargement: Benign prostatic hyperplasia, Publication 07-3012, NIH, Bethesda, (2006).
8. Sharma, C.R., Akhtar, J., Jagani, N.M., Shankharva, Y.R., Shah, J.S.; UV spectrophotometric method for estimation of silodosin from its solid dosage form; Inventi Rapid: Pharm Analysis & Quality Assurance, http://www.inventi.in/Article/ppaqa/310/12.aspx (accessed December 2, 2012).
9. Chinnalalaiah, R., Ravikumar, P.; Development and validation of RP-HPLC method for estimation of silodosin in bulk and pharmaceutical dosage forms; International Journal of Pharmaceutical Sciences Review and Research, (2012); 16: 52-55.
10. Matsubara, Y., Kanazawa, T., Kojima, Y., Abe, Y., Kobayashi, K., Kanbe, H., et al.; Pharmacokinetics and disposition of silodosin; Journal of the Pharmaceutical Society of Japan, (2006); 126: 237-245.
11. Zhao,X., Liu,Y., Xu, J., Zhang, D.,Zhou, Y.,Gu, J., et al.; Determination of Silodosin in human plasma by liquid chromatography-tandemmass spectrometry; Journal of Chromatography B, (2009); 877: 3724-3728.
12. International Conference on Harmonization (ICH); Q2 (R1), Validation of Analytical Procedures: Text and Methodology, (2005). http://www.ich.org/LOB/ media/MEDIA 417.pdf (accessed December 23, 2010).
13. United States Pharmacopoeia (USP); Validation of Compendial Methods (31st edition). United States Pharmacopeial Convention, Rockville, MD, (2008).